Document Detail

Ambrisentan and its role in the management of pulmonary arterial hypertension.
MedLine Citation:
PMID:  19198697     Owner:  NLM     Status:  MEDLINE    
Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety.
Iain M Macintyre; Neeraj Dhaun; Jane Goddard; David J Webb
Related Documents :
1565817 - Changes in spirometry during consecutive admissions for infective pulmonary exacerbatio...
15136907 - Restrictive ventilatory impairment and arterial oxygenation characterize rest and exerc...
24195627 - Appetite sensations and substrate metabolism at rest, during exercise, and recovery: im...
1768827 - Preoperative cardiopulmonary exercise testing: determining the limit to exercise and pr...
11317177 - Effects of pefloxacin on urinary and salivary concentrations of isoniazid in six health...
8857497 - Skeletal muscle hypoperfusion during recovery from maximal supine bicycle exercise in p...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  44     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2009-02-09     Completed Date:  2009-05-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  875-85     Citation Subset:  IM    
Copyright Information:
Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Clinical Pharmacology Unit, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Clinical Trials as Topic
Drug Interactions
Follow-Up Studies
Hypertension, Pulmonary / drug therapy*,  physiopathology
Phenylpropionates / pharmacokinetics,  therapeutic use*,  toxicity
Pyridazines / pharmacokinetics,  therapeutic use*,  toxicity
Receptor, Endothelin A / antagonists & inhibitors*,  therapeutic use
Reg. No./Substance:
0/Antihypertensive Agents; 0/Phenylpropionates; 0/Pyridazines; 0/Receptor, Endothelin A; 177036-94-1/ambrisentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pediatric Asthma and Problems in Attention, Concentration, and Impulsivity: Disruption of the Family...
Next Document:  Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia.